24.01.2011 • News • IMCD • BASF • Trimethylolpropane

IMCD Group Strengthens Partnership with BASF

IMCD Group has announced that it will act as BASF's distribution partner for the company's polyalcohol range. IMCD will be responsible for servicing the small- and medium-sized customers within the European market.

Polyalcohols are widely used as building blocks for resins in paints, coatings and adhesives. In addition to Neol Neopentylglycol, where IMCD has had a long lasting partnership with BASF, the new partnership includes trimethylolpropane, HDO1,6-Hexanediol, 1,5-Pentanediol and Hydroxypivalic acid neopentylglycolester.

 

 

Company

Logo:

IMCD Group B.V.

Wilhelminaplein 32
3072 Rotterdam
Netherlands

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.